Phase 1b trial results published
The Phase 1b clinical trial is detailed in a new article in European Urology Open Science.
News about various clinical trials we are participating in.
The Phase 1b clinical trial is detailed in a new article in European Urology Open Science.
180 days post single treatment results: 45% complete response, 22% partial response, 11% no response, 22% yet undetermined (n=11). Taken from the Theralase 2020Q4 newsletter.
The U.S. Food and Drug Administration has granted Fast Track Designation to the Phase II Non-Muscle Invasive Bladder Cancer clinical study, opening the possibility of an Accelerated Approval and Priority Review. More details can be found at the Theralase press release.